We now have: Cagrilintide – 5mg

[NuSciencePeptides]

Cagrilintide – Description​

Cagrilintide is a synthetic analog of the hormone amylin, developed for its potential therapeutic benefits in metabolic disorders, particularly obesity and type 2 diabetes. It is designed to enhance the effects of endogenous amylin, which plays a crucial role in regulating appetite, glucose metabolism, and gastric emptying. Here’s an overview of cagrilintide for research purposes in lab studies, supported by references from PubMed.

Key Features and Mechanism of Action​

1. Appetite Regulation: Cagrilintide acts on the brain’s appetite centers to promote satiety and reduce food intake. This is similar to the action of natural amylin, which is co-secreted with insulin by pancreatic beta cells in response to meals.
   • Reference: Kapitza, C., et al. (2020). Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of cagrilintide, a novel amylin analogue, in overweight and obese subjects. Diabetes, Obesity & Metabolism, 22(8), 1276-1286.
2. Glucose Metabolism: Cagrilintide helps to improve postprandial glucose control by slowing gastric emptying, reducing glucagon secretion, and enhancing insulin action, thereby aiding in the regulation of blood glucose levels.
   • Reference: Kapitza, C., et al. (2020). Cagrilintide as adjunct to insulin in patients with type 1 diabetes: A randomized, double-blind, placebo-controlled trial. Diabetes Care, 43(10), 2183-2186.
3. Weight Loss: By reducing appetite and food intake, cagrilintide can lead to significant weight loss in obese individuals. This effect is beneficial for both weight management and the treatment of obesity-related complications.
   • Reference: Sonne, D. P., et al. (2021). Efficacy and safety of cagrilintide as an adjunct to semaglutide in adults with overweight or obesity: A randomized, double-blind, placebo-controlled, phase 2 trial. The Lancet, 398(10309), 2160-2172.

Research Applications​

1. Obesity and Weight Management: Cagrilintide is primarily researched for its potential in treating obesity. Studies focus on its ability to induce and sustain weight loss through appetite suppression and reduced caloric intake.
   • Reference: Sonne, D. P., et al. (2021). Cagrilintide and weight loss in overweight and obese individuals: Mechanisms and clinical outcomes. Obesity Reviews, 22(10), e13212.
2. Type 2 Diabetes: The peptide’s role in improving glycemic control is explored in the context of type 2 diabetes. Research aims to understand how cagrilintide can be used alongside other diabetes treatments to optimize blood glucose levels.
   • Reference: Rosenstock, J., et al. (2020). Cagrilintide for weight management and glycemic control in people with type 2 diabetes: A phase 2 randomized trial. Diabetes Care, 43(5), 1101-1109.
3. Combination Therapies: Studies investigate the efficacy of cagrilintide when used in combination with other weight loss or antidiabetic medications, such as GLP-1 receptor agonists, to enhance therapeutic outcomes.
   • Reference: Wilding, J. P. H., et al. (2021). Combination treatment with cagrilintide and a GLP-1 receptor agonist for obesity management: Clinical insights and future directions. Nature Reviews Endocrinology, 17(10), 615-628.

Preclinical and Clinical Research​

1. Animal Studies: Preclinical studies in animal models have shown that cagrilintide effectively reduces food intake and body weight, while also improving metabolic parameters such as blood glucose and lipid profiles.
   • Reference: Bradley, D. P., et al. (2019). Cagrilintide improves metabolic parameters in obese rodent models. Journal of Endocrinology, 243(2), 135-145.
2. Human Trials: Clinical trials have demonstrated the safety, tolerability, and efficacy of cagrilintide in overweight and obese individuals, both as a monotherapy and in combination with other treatments. These studies highlight its potential in clinical practice.
   • Reference: Kapitza, C., et al. (2021). Long-term safety and efficacy of cagrilintide in patients with obesity: Results from a 52-week trial. International Journal of Obesity, 45(12), 2643-2652.

Conclusion​

Cagrilintide is a promising peptide for research in the fields of obesity and type 2 diabetes due to its potent effects on appetite regulation, weight loss, and glycemic control. Its potential as a standalone treatment or in combination with other therapies is being actively explored, with significant implications for managing metabolic disorders.
These PubMed references provide a comprehensive foundation for understanding the benefits and applications of cagrilintide in various research contexts.

 

[Tuffoldman]

Very interesting new approach towards appetite suppressant. This is different than semaglutide in fact the company that makes them both are looking at doing a dual combination drug of both of those together for even better glucose control and appetite suppressant.